TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28353023
Drug: Biotene Oralbalance
Normalized name: BIOTENE
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotene Oralbalance mouthwash plus gel
Study: 12752890
Drug: Intravenous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conjugated equine oestrogen (25 mg)
Study: 11082823
Drug: Active transdermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal nicotine patch
Study: 9337508
Drug: Psychodynamic-interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic-interpersonal therapy
Study: 25616881
Drug: Promethazine 6.25
Normalized name: DM 15/PROMETHAZINE 6.25MG/5ML SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 6.25 mg IV
Study: 25616881
Drug: Promethazine 12.5
Normalized name: promethazine 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 12.5 mg IV
Study: 18279487
Drug: Aminophylline 3
Normalized name: aminophylline 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 3 mg x kg(‐1)
Study: 16006428
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.5 g/d)
Study: 12598354
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine with montanide ISA 51 as adjuvant
Study: 12598354
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine with aluminum hydroxide as adjuvant
Study: 12598354
Drug: Cyclophosphamide prevaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide prevaccination treatment
Study: 12598354
Drug: EGF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF vaccine (five doses)
Study: 9890172
Drug: Vinorelbine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine treatment (intravenous on days 1 and 8 of a 21-day cycle for six cycles)
Study: 9890172
Drug: Vinorelbine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine treatment
Study: 15374185
Drug: Dihydroergokryptine (DEK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergokryptine (DEK) 5 mg bid for 2 weeks, 10 mg bid for 2 weeks, 20 mg bid for 11 months
Study: 1856491
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (ABLC) at doses of 0.1, 0.25 mg/kg; 0.5 mg/kg not given to AB group.
Study: 1856491
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B desoxycholate (AB) at doses of 0.1, 0.25 mg/kg.
Study: 30987662
Drug: Chuna manual
Normalized name: China-Gel
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuna manual therapy (CMT)
Study: 30987662
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CMT + UC)
Study: 24365987
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole at a dose of 0.5 mg/kg twice daily
Study: 24365987
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole at a dose of 1 mg/kg twice daily
Study: 17325558
Drug: PG4 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG4 group (control formula supplemented with 4 g/L of a prebiotic blend, n = 74)
Study: 17325558
Drug: PGL8 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGL8 group (control formula supplemented with 8 g/L of a prebiotic blend, n = 76)
Study: 14723561
Drug: Cetuximab 400
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m2 initial dose followed by 250 mg/m2 weekly plus irinotecan (various doses)
Study: 7920748
Drug: GnRH analogue,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analogue, goserelin (Zoladex), 3.6 mg/inj monthly for 6 months
Study: 31499227
Drug: Health coaching
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health coaching intervention with 10 live coaching sessions delivered virtually by health coaches using tablets.
Study: 31499227
Drug: Standardized health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized health information via tablets
Study: 28596245
Drug: Computerised cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive-behavioural therapy (cCBT)
Study: 28596245
Drug: Psychiatric treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychiatric treatment as usual (TAU)
Study: 23319454
Drug: Modified Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Cognitive Behavioral Therapy (mCBT)
Study: 21764662
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tirofiban (HDT)
Study: 12393605
Drug: TAD/HAM double
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD/HAM double induction, TAD consolidation, and either maintenance therapy or S-HAM consolidation
Study: 8648777
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral fleroxacin once daily
Study: 6145727
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug therapy (control)
Study: 31520897
Drug: apabetalone 100
Normalized name: Apabetalone
DrugBank: Apabetalone (DB12000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apabetalone 100 mg orally twice daily
Study: 23924261
Drug: Aspirin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (240 mg/day)
Study: 20008230
Drug: Novel monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel monoclonal antibodies targeting CD20, CD23, or CD40
Study: 15520364
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 to 40 mg/d)
Study: 15520364
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 to 45 mg/d)
Study: 11883741
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg administered once daily via Turbuhaler
Study: 9683002
Drug: MgSO4 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO4 (3 g MgSO4 between 2030 hours and 2100 hours, followed by 0.5 g MgSO4 per hour until 0700 hours)
Study: 8062317
Drug: Diltiazem XR
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem XR (240 mg, then 480 mg after 4 weeks if DBP > 90 mm Hg)
Study: 29678370
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg octanoic acid (OA)
Study: 26179823
Drug: Pictorial self‐adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictorial self‐adhesive prescriptions
Study: 26179823
Drug: Handwritten drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handwritten drug charts
Study: 26188642
Drug: LCPUFAs (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFAs (1.4 g of eicosapentaenoic and docosahexaeonic acids)
Study: 24307845
Drug: Enteric-coated alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated alendronate (5 mg) and calcitriol (0.5 µg) combined drug (Maxmarvil)
Study: 9327193
Drug: Quinapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (2.5 mg once-daily)
Study: 9327193
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg twice-daily)
Study: 6942649
Drug: Sucrose supplement
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose supplement
Study: 10352053
Drug: New intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: New intravenous therapy protocol
Study: 10352053
Drug: Old intravenous
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old intravenous therapy protocol
Study: 10352053
Drug: Nurses' judgments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses' judgments related to intravenous therapy initiation
Study: 8618811
Drug: rhuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuEPO treatment for 12 months
Study: 2202791
Drug: AC therapy
Normalized name: CARDIAC THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC therapy
Study: 6814757
Drug: VM-26 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: VM-26 and hexamethylmelamine as single agents
Study: 30590411
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (400 or 800 μg per day)
Study: 30590411
Drug: Creatine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (3 g per day)
Study: 30590411
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (800 µg)
Study: 23364814
Drug: Cocoa polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa polyphenols (500 mg)
Study: 23364814
Drug: Cocoa polyphenols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa polyphenols (250 mg)
Study: 12656907
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg every 12 hours plus Vitamin E 600 mg/day for 6 months
Study: 12656907
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg/day for 6 months
Study: 11252642
Drug: Nimodipine and
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine and related dihydropyridine calcium channel blockers
Study: 11252642
Drug: Unimodal antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unimodal antidepressants
Study: 8820469
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate 25, 50, 100, 150, or 200 mg
Study: 6475177
Drug: teopranitol (KC
Approvals — FDA: no, EMA: no, PMDA: no
Description: teopranitol (KC 046) 0.04 mg/kg body weight
Study: 31586022
Drug: Romiplostim (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (weekly subcutaneous injections)
Study: 29577710
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing with Low Level Laser Therapy (LLLT)
Study: 27354368
Drug: 15 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 µg GI.1 VLP and 50 µg GII.4 VLP (15/50 formulation)
Study: 27354368
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg GI.1 VLP and 50 µg GII.4 VLP (50/50 formulation)
Study: 17594068
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for abdominal aneurysms
Study: 20929990
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (rosiglitazone, metformin, and any insulin)
Study: 8915969
Drug: Starting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting treatment with diuretics
Study: 8915969
Drug: Starting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting treatment with beta-blockers
Study: 8915969
Drug: Starting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting treatment with angiotensin-converting enzyme inhibitors
Study: 1918302
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Norditropin, Novo Nordisk Gentofte A/S) 24 IU intramuscular injections on alternate days
Study: 6225984
Drug: spectinomycine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: spectinomycine 2 g
Study: 6225984
Drug: ampicillin +
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ampicillin + probenecide 3.5 g + 1 g
Study: 6225984
Drug: thiamphenicol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiamphenicol 2.5 g
Study: 6225984
Drug: minocycline 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: minocycline 300 mg
Study: 29177461
Drug: Randomized clinical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized clinical trials for evaluating treatments and vaccines during the Ebola epidemic
Study: 27009916
Drug: Sifalimumab 200
Normalized name: Sifalimumab
DrugBank: Sifalimumab (DB12773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifalimumab 200 mg
Study: 27009916
Drug: Sifalimumab 600
Normalized name: Sifalimumab
DrugBank: Sifalimumab (DB12773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifalimumab 600 mg
Study: 27009916
Drug: Sifalimumab 1200
Normalized name: Sifalimumab
DrugBank: Sifalimumab (DB12773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sifalimumab 1200 mg
Study: 24756514
Drug: Acetazolamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (up to 4 g/d) with low-sodium weight-reduction diet
Study: 22789509
Drug: Rotarix (rotavirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix (rotavirus vaccine)
Study: 22789509
Drug: Vivotif (typhoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivotif (typhoid vaccine)
Study: 22789509
Drug: ACAM2017 (candidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAM2017 (candidate vaccine against ETEC)
Study: 8750154
Drug: 5‐FU 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 400 mg/m2/d and FA 200 mg/m2/d i.v. on days 1‐5, TP‐5 50 mg s.c. on days 8‐11, and IL‐2 9 MU/m2 s.c. twice daily on days 12‐16
Study: 6681970
Drug: Slow-release furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release furosemide (Eutensin) 40 mg
Study: 6681970
Drug: Furosemide tablets
Normalized name: Furosemide Tablets
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide tablets (Lasix) 40 mg
Study: 25349362
Drug: Tilmicosin at
Normalized name: Tilmicosin
DrugBank: Tilmicosin (DB11471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilmicosin at 10 mg/kg BW (TIL)
Study: 25349362
Drug: Tulathromycin at
Normalized name: tulathromycin
DrugBank: Tulathromycin A (DB11474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulathromycin at 2.5 mg/kg BW (TUL)
Study: 25349362
Drug: No metaphylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No metaphylactic treatment (ND)
Study: 20298120
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antioxidants (single or double dose)
Study: 19298018
Drug: Erythropoietin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin and tranexamic acid (TA) administered to selected patients in the study group of 133 patients.
Study: 7854375
Drug: Dapsone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (50 mg)
Study: 1776338
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 x 8 mg/d)
Study: 1776338
Drug: ASA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (1 x 500 mg/d) plus nifedipine (3 x 20 mg/d)
Study: 7014183
Drug: Metoclopramide (Cerucal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (Cerucal, 10 mg i.v. or p.o.)
Study: 28509727
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blockers (CCBs) in participants without a history of cardiovascular disease
Study: 28509727
Drug: Calcium Channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel Blockers (CCBs) in participants with uncontrolled hypertension
Study: 28509727
Drug: Any other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any other antihypertensive medication (Control)
Study: 25272094
Drug: Pregabalin (75-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (75-600 mg/d for DPN, 150-600 mg/d for PHN)
Study: 18357434
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition supplemented with fish oil (n-3/n-6 ratio of 1:2)
Study: 18357434
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral nutrition (n-3/n-6 ratio of 1:7)
Study: 3631561
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (2 mg/min) started 30 min before operation and continued for 24 hr after surgery (n = 18)
Study: 3631561
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (2 mg/min)
Study: 3631561
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (n = 20)
Study: 22099890
Drug: 4% articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 1:100,000 epinephrine via buccal infiltration (B Infil)
Study: 18306855
Drug: MVE ceramide-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVE ceramide-containing liquid cleanser and moisturizing cream plus fluocinonide cream 0.05%
Study: 18306855
Drug: Bar cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar cleanser plus fluocinonide cream 0.05%
Study: 17181872
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily water intake by 1 litre/d
Study: 8765618
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose RSVIG (750 mg/kg monthly)
Study: 8765618
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose RSVIG (150 mg/kg monthly)
Study: 1544195
Drug: Droperidol 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.075 mg.kg-1
Study: 12587480
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) solution
Study: 2865926
Drug: Other calcium
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other calcium antagonists
Study: 26913407
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group (DC-CIK + chemotherapy)
Study: 15812748
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice of postdischarge beta-blocker initiation
Study: 3018566
Drug: Captopril, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 150 mg daily
Study: 3018566
Drug: Enalapril, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 40 mg daily
Study: 29984884
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive therapy (target SBP < 120 mm Hg)
Study: 29984884
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive therapy (target SBP < 140 mm Hg)
Study: 29984884
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (intensive and standard)
Study: 24633589
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) training at low 12 Hz frequency, 10 weeks, twice-a-week
Study: 20237125
Drug: Infliximab plus
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab plus methotrexate (mean dose 4.4 mg/kg per infusion, administered every 8 weeks)
Study: 16187871
Drug: Cortisol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (20 mg and 40 mg)
Study: 20961269
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg/day)
Study: 31383430
Drug: Manual Cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Cranial Therapy (MC-t)
Study: 31383430
Drug: Massage Therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage Therapy (Mss-t)
Study: 23187069
Drug: Group psychological
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychological intervention based on cognitive behavioral therapy and motivational interviewing
Study: 18061271
Drug: Topical and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical and intracameral anesthesia (supplementary intracameral lidocaine)
Study: 12777909
Drug: Murine monoclonal
Normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab)
Study: 10700898
Drug: UFT oral
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT oral administration for one year at 3-4 capsules daily
Study: 10700898
Drug: CDDP i.p.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP i.p. administration of 70 mg/m2 at the time of resective surgery
Study: 8251021
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (15 ml per day containing 3.1 g of omega-3 fatty acids)
Study: 3693871
Drug: Nitrazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam (2.5 mg)
Study: 26687902
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose radiotherapy (54 Gy/36f/12 days to 57.6 Gy, 61.2 Gy, and 64.8 Gy)
Study: 26687902
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose radiotherapy
Study: 23001893
Drug: Concurrent palliative
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent palliative care